Hbis Company Limited (000709.SZ) plans to invest 7.967 billion yuan to build a wide plate project in its subsidiary.
Hesteel Group (000709.SZ) announced that in order to optimize the company's product structure and create a high-quality, efficient, green, and intelligent domestic leading wide and thick plate production base with special steel varieties as its feature, to continuously enhance the company's market competitiveness, the company's holding subsidiary, Hegang Leting Iron and Steel Co., Ltd. (hereinafter referred to as "Leting Company"), plans to invest in the construction of a new 5600mm hot-rolled wide and thick plate production line, with a total investment of 7.967 billion yuan. After the project is completed, it can produce a total of 2.42 million tons of qualified finished products per year.
Hbis Company Limited (000709.SZ) announced that, in order to optimize the company's product structure and create a high-quality, efficient, green, and intelligent domestic leading wide and thick plate production base with specialty steel as the feature, the company's controlling subsidiary, Hegang Leting Iron and Steel Co., Ltd. (hereinafter referred to as "Leting Company"), plans to invest in building a new 5600mm hot-rolled wide and thick plate production line with an investment of 7.967 billion yuan. Once the project is completed, it will have an annual production capacity of 2.42 million tons of qualified products.
The wide and thick plate project will focus on high-end products such as shipbuilding and marine engineering plates, wind power tower plates, and low-alloy steel structural plates, supplemented by other products such as carbon steel structural plates, engineering machinery plates, and pipeline steel. This will help further optimize the company's product structure, promote the transformation and upgrading to high value-added products, and significantly enhance the company's product market competitiveness.
Related Articles

TOP EDUCATION (01752) issued 60.16 million shares due to the exercise of rights to performance before the initial public offering.

DEEP SOURCE(00990) spent 540,000 Hong Kong dollars to repurchase 1 million shares on July 23rd.

Chengdu Kanghong Pharmaceutical Group (002773.SZ): Hongji Biological's self-developed AAV gene therapy product KHN921 injection has been approved for clinical trials of drugs.
TOP EDUCATION (01752) issued 60.16 million shares due to the exercise of rights to performance before the initial public offering.

DEEP SOURCE(00990) spent 540,000 Hong Kong dollars to repurchase 1 million shares on July 23rd.

Chengdu Kanghong Pharmaceutical Group (002773.SZ): Hongji Biological's self-developed AAV gene therapy product KHN921 injection has been approved for clinical trials of drugs.

RECOMMEND





